Experience with xeloda (capecitabine) as a component of chemotherapy for relapsing and cisplatin-resistant ovarian tumors

Voprosy Onkologii

Volumn 49, Issue 2, 2003, Pages 193-197

  Makhnova, Ye V ^a   Gershanovich, M L ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; PRODRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; EVALUATION; FEMALE; HUMAN; LEUKOPENIA; NEUTROPENIA; OVARY CARCINOMA; PROGNOSIS; VOMITING; DRUG ADMINISTRATION; DRUG RESISTANCE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; OVARY TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PRODRUGS; TREATMENT OUTCOME;

EID: 0038205609     PISSN: 05073758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Cartwright T.H., Cohn A., Varkey U.A. et.al. Phase II study of oral capecitabine in patients with advanced metastatic pancreatic cancer // Clin. Oncol. - 2002. - Vol. 20. - P. 160-164.
2. Fujwaki R., Hata K., Nakayama K. et. al. Gene expression for dihydropyrimidine dehydrogenase and outcome in epitelial ovarian cancer // J. Clin. Oncol. - 2002. - Vol. 18, No23. - P. 3946-3951.
3. Gore M. Treatment of relapsed epithelial ovarian cancer // ASCO 2001. - Educational Book. - P. 468-476.
4. Mackean M., Planting A., Twelves C. et.al. Phase I and pharmacological study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer // J. Clin. Oncol. - 1998. - Vol. 16. - P. 2977-2985.
5. Miwa M., Ura M., Nishida M. et.al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectivity in tumors by enzymes concentrated in human liver and cancer tissue // Europ. J. Cancer. - 1998. - Vol. 34. - P. 1274-1281.
6. Sikora K., Advani S., Koroltchouk V. et.al. Essential drugs for cancer therapy: A Worker Health Organization consultation // Ann. Oncol. - 1999. - Vol. 10. - P. 385-390.
7. Vasey P., McMahon L., Paul J. et.al. A phase II trial of capecitabine in relapsed ovarian cancer // Ibid. - 2000. - Vol. 11 (Suppl. 4). - P. 84. - Abstr. 373 p.
8. Wolf J.K., Sur C.C., Verschraegen C.F. et.al. A phase II study of Xeloda in patients with chemotherapy resistant recurrent ovarian cancer // Proc. ASCO. - 2002. - P. 224. - Abstr. 893.